Semaglutide (Wegovy) vs Tirzepatide (Zepbound)

Both Wegovy and Zepbound were evaluated in large, rigorous clinical trial programs, though no direct head-to-head trial has been completed between semaglutide 2.4 mg and tirzepatide for weight management specifically.

Wegovy was studied in the STEP program ^[3]. STEP 1, the pivotal trial, enrolled 1,961 adults with obesity (or overweight with comorbidities) without type 2 diabetes. At 68 weeks, the mean body weight reduction was 14.9% with semaglutide 2.4 mg versus 2.4% with placebo ^[3]. Approximately 32% of participants lost 20% or more of their body weight. The SELECT cardiovascular outcomes trial (2023) demonstrated a 20% reduction in major adverse cardiovascular events in overweight/obese adults with established CV disease but without diabetes ^[5].

Zepbound was studied in the SURMOUNT program ^[4]. SURMOUNT-1, the pivotal trial, enrolled 2,539 adults with obesity (or overweight with comorbidities) without type 2 diabetes. At 72 weeks, mean weight reductions were: tirzepatide 5 mg: -15.0%; tirzepatide 10 mg: -19.5%; tirzepatide 15 mg: -20.9%; placebo: -3.1% ^[4]. At the highest dose, approximately 36% of participants lost 25% or more of their body weight ^[4].

Comparing across trials (with the caveat that cross-trial comparisons have inherent limitations due to different study populations, designs, and time frames), Zepbound at its maximum dose of 15 mg appears to produce approximately 5-6 percentage points more weight loss than Wegovy's 2.4 mg dose ^[3][4]. The SURMOUNT-5 trial, which directly compares tirzepatide and semaglutide for weight management, is expected to provide definitive head-to-head data.

In the type 2 diabetes population, the SURPASS-2 trial compared tirzepatide to semaglutide 1 mg (not 2.4 mg) and showed superior weight loss with tirzepatide, though this involved different doses than the weight management formulations ^[8].

Both medications show that weight tends to be regained after discontinuation, underscoring the chronic nature of obesity treatment ^[6][9].

Both Wegovy and Zepbound cause gastrointestinal side effects as their most common adverse reactions, consistent with their incretin-based mechanisms of action ^[1][2].

In STEP 1 for Wegovy, the most common adverse events were nausea (44.2% vs. 17.4% placebo), diarrhea (30.0% vs. 15.7%), vomiting (24.8% vs. 6.4%), constipation (24.2% vs. 11.1%), and abdominal pain (19.4% vs. 10.3%) ^[3]. Treatment discontinuation due to adverse events was 7.0% versus 3.1% with placebo ^[3].

In SURMOUNT-1 for Zepbound, the most common adverse events across doses were nausea (24-33%), diarrhea (18-25%), constipation (11-17%), vomiting (6-13%), and injection site reactions (3-7%) ^[4]. Treatment discontinuation due to adverse events was 4.3-7.1% across tirzepatide doses versus 2.6% with placebo ^[4].

Direct comparison of side effect rates across trials is imprecise, but the available data suggest that gastrointestinal side effects may occur at somewhat lower rates with tirzepatide than semaglutide 2.4 mg, despite tirzepatide producing greater weight loss ^[3][4]. This may reflect differences in receptor pharmacology or dose titration schedules.

Both medications carry identical boxed warnings for thyroid C-cell tumors and share contraindications for medullary thyroid carcinoma and MEN 2 ^[1][2]. Both carry warnings for pancreatitis, gallbladder disease, hypoglycemia, acute kidney injury, suicidal ideation, and hypersensitivity reactions ^[1][2].

Wegovy and Zepbound are both premium-priced, brand-name medications without generic alternatives ^[1][2].

Wegovy has a list price of approximately $1,349 per month ^[1]. Zepbound launched at a list price of approximately $1,060 per month, making it somewhat less expensive at list price ^[10]. Eli Lilly also introduced LillyDirect, offering Zepbound through a direct-to-patient pharmacy program at potentially lower out-of-pocket costs ^[10].

Insurance coverage for both medications remains a significant barrier. Because they are classified as anti-obesity medications, many insurance plans exclude them from coverage ^[7]. Medicare Part D has historically not covered weight loss drugs, though legislative efforts are ongoing to change this. Commercial coverage varies widely by plan and employer.

Novo Nordisk offers a Wegovy savings program for eligible commercially insured patients ^[1]. Eli Lilly offers a Zepbound savings card that can reduce costs to as low as $25 per month for eligible patients with commercial insurance ^[10]. For patients without insurance coverage, Eli Lilly has also offered Zepbound through LillyDirect at a cash price lower than the list price.

The out-of-pocket cost landscape for anti-obesity medications is evolving rapidly, with policy changes, manufacturer pricing strategies, and insurance coverage decisions all in flux.

Both Wegovy and Zepbound are once-weekly subcutaneous injections, providing a similar level of convenience in terms of dosing frequency ^[1][2].

Wegovy uses prefilled, single-dose pens in five strengths for titration (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg) ^[1]. The full dose escalation to the maintenance dose of 2.4 mg takes approximately 16-20 weeks ^[1]. Pens must be refrigerated before first use and can be stored at room temperature for up to 28 days ^[1].

Zepbound uses single-dose autoinjectors available in six strengths (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg) ^[2]. The dose escalation period takes approximately 20-28 weeks to reach the maximum dose of 15 mg ^[2]. Autoinjectors must be refrigerated before use and can be stored at room temperature for up to 21 days ^[2].

Zepbound's autoinjector is generally considered easier to use than a pen injector, requiring fewer steps ^[2]. However, Wegovy's slightly longer room-temperature storage window offers a minor practical advantage ^[1].

The choice between Wegovy and Zepbound should be guided by clinical evidence, individual health factors, insurance coverage, and discussions with your healthcare provider ^[1][2].

Based on available clinical trial data, Zepbound at its maximum dose appears to produce greater weight loss than Wegovy (approximately 20.9% vs. 14.9% body weight reduction) ^[3][4]. For patients whose primary goal is maximum weight loss and who tolerate the medication well, this difference is clinically meaningful and could influence the decision.

However, Wegovy has a longer track record in weight management (approved 2021 vs. 2023 for Zepbound) and critically, has completed a cardiovascular outcomes trial (SELECT) demonstrating a 20% reduction in major adverse cardiovascular events ^[5]. For patients with established cardiovascular disease, this evidence provides additional confidence in Wegovy's benefits beyond weight loss. Zepbound's cardiovascular outcomes trial (SURMOUNT-MMO) is ongoing.

Insurance coverage and cost often determine access ^[7][10]. If your insurance covers one but not the other, that practical reality may guide the decision. Both medications are expensive without coverage, though Zepbound's list price and direct-to-patient programs may offer slight cost advantages ^[10].

Some patients may respond better to or tolerate one medication over the other, and individual responses can vary. If the first medication tried is not well tolerated or does not produce adequate results after sufficient time, switching to the alternative may be appropriate.

This information is for educational purposes only and does not constitute medical advice. Always consult your healthcare provider to determine the most appropriate treatment for your individual situation.